


REVIEW



For a competition for employment of AD "Professor", in the field of higher education 7. "Health and sport", professional direction 7.3. "Pharmacy", in the scientific specialty "Pharmacoeconomics and pharmaceutical regulation" for the needs of the department "Organization and economics of pharmacy" at the Faculty of Pharmacy of the Medical University - Plovdiv, announced in the Official Gazette, no. 47/04/06/2024

With a single candidate admitted to the competition: Assoc. Prof. Stanislav Radoslavov Georgiev, MSc. Pharm., Ph.D.

By: Prof. Georgi Momekov, D.Sc.;

with board-certified specialties "Pharmacology and Pharmacotherapy" and "Clinical Pharmacy", Head of the Department of "Pharmacology, Pharmacotherapy and Toxicology" at the Medical University - Sofia, elected as a member of the scientific jury under this procedure, in compliance with order No. R-2650 of 07.08.2024 by order of the Rector of MU-Plovdiv.

Preamble

The documents for the competition were provided to me by the only admitted candidate - Assoc. Stanislav Radoslavov Georgiev, M.Sc. Pharm., Ph.D. The materials and documents provided to me for review have been prepared in accordance with the relevant regulatory framework - Art. 4 and 26 of ZRASB, the Regulations and its application and the Regulations for the organization and activities of MU-Plovdiv. The documents have been prepared in an exemplary manner and all the regulatory requirements of the procedure have been met.

1. Biographical data, career development and work experience.

Assoc. Stanislav Georgiev, MSc. Pharm., Ph.D., completed his higher education with the Master of Pharmacy degree in 1999 at the Faculty of Pharmacy of the Medical University of Sofia. His first professional realization was in the distribution company for wholesale trade with medicinal products Gloria International Limited EOOD, where he joined immediately after graduation. The following year, he started working as a medical representative in the TA of GSK in Bulgaria, and from 2004 to 2006 he worked in the commercial representation of Boehringer Ingelheim. In the period 2001 - 2007, Assoc. Prof. Georgiev was a part-time doctoral student, enrolled in the Department of "Organization and Economics of Pharmacy" at the Medical University - Sofia, Faculty of

Pharmacy, and in 2007 he successfully defended his dissertation titled "Study of the possibilities for the implementation of pharmaceutical care in pharmacy practice" and acquires the Educational and scientific degree "Doctor (PhD)", according to the profile of the current competition. Assoc. St. Georgiev has board-certified specialties in "Organization and economics of distribution and pharmacy practice" (2012), and in "Hospital pharmacy" (2020), at the FPh training base, MU - Sofia.

His academic career has been realized entirely at the MU-Plovdiv, where after a competition he was appointed in 2008 and successively held the positions of assistant (2008), ch. assistant (2012) and associate professor (2012), and from 2015 to 2019 he was the deputy dean for academic activities of the FF at the MU - Plovdiv. Assoc. Prof. Georgiev is a member of a number of authoritative organizations, commissions, expert panels, as follows: Expert council on activities in organization and economy, drug technology and hospital pharmacy at the Minister of Health; Ethics Committee of the BFS Board of Directors; Retail Trade Expert Council at BDA; Specialized Commission on Herbal Medicinal Products to the Executive Director of BDA; Specialized Commission for determining the affiliation of medicinal products to the Executive Director of BDA; Bulgarian Scientific Society of Pharmacy. Assoc. Prof. Georgiev is a member of the Faculty Council of the Faculty of Pharmacy at MU-Plovdiv of the relevant state examination commissions for the profile of his specialty.

2. Scientific research activity, publication activity and scientometric parameters.

For his participation in the current competition for AD "Professor" Assoc. Prof. Georgiev has provided a list and copies of 41 real full-text publications, including 23 articles in refereed journals and 18 in non-refereed editions, dissertation work for the acquisition of the PhD degree, habilitation work - monograph, as well as 2 chapters of collective monographs. A total of 11 teaching aids and textbooks are also provided. In accordance with the normative framework relevant to the competition, these publications were realized after the primary habilitation of Assoc. Prof. Georgiev

As can be seen from the reference submitted by the candidate, 136 independent citations have been identified for his scientific works, of which 48 are in the Scopus database. According to Scopus data, Assoc. Prof. Georgiev's Hirsch index is 4.

The scientific interests and respectively realized contributions of Assoc. Prof. Georgiev are representative for a multifaceted research work, the key areas of which can be summarized as follows: drug interactions, self-management, pharmaceutical care, pharmacoeconomics and pharmaceutical regulation, theoretical foundations and problems related to the training of pharmacy students.

In connection with the problems arising when combining drugs, a specialized study was conducted on the awareness of patients regarding drug use (application, adherence to

drug therapy) and identification of possible adverse events, among Bulgarian patients taking 5 or more medicinal products. The analysis of the obtained data gives the author reason to conclude that it is imperative to introduce the specific pharmaceutical service "Drug review" in the national pharmaceutical practice, which will allow to institutionalize the role of pharmacists as key consultants and monitors of drug therapy and minimize the risk of unwanted drug events caused by polypharmacy and unsuccessful combinations of co-administered medicinal products.

The dynamics of spontaneously reported adverse drug reactions in our country has also been monitored, and a trend has been established for a stable growth of reports received annually. The author concludes that the existing approaches and methodical set of pharmacovigilance are not adequate to identify potentially important adverse drug reactions, especially in some classes of medicinal products, and valuable recommendations are made for the potential optimization of post-marketing control mechanisms, approaches and options of adverse drug events.

In the publications provided, there is also an analysis of the dynamic changes in the regulatory framework and registration regime of dietary supplements, which is of great interest due to the markedly growing interest in natural products and alternative medicine modalities on the one hand, and the well-established problems and pitfalls, related to this type of products and especially their underestimated potential for unwanted effects, interactions and toxicity, especially in the presence of impurities or intentionally inserted into their composition and undeclared synthetic substances, including drug molecules.

Another area of interest, especially in light of the 2020 pandemic, is regulatory approaches and public health issues in the context of infectious diseases, particularly those with pandemic potential. The applicant has analyzed specific medicinal products and vaccines provided to Member States through the mechanism of Joint Public Procurement for Medical Countermeasures, and in these studies the overall impact of access to the relevant medicines has been monitored in terms of global parameters of public health. A key study tracked data at national and European level on access and availability of the antiviral drug with proven clinical benefit in SARS-CoV-2, Remdesivir, where there were significant asymmetries in access to treatment caused not least by and from the drastic irrational use and its inclusion in patients in whom no clinical benefits are expected in the framework of the large-scale program for its clinical evaluation - mild forms of the disease or terminal, severe forms of the hyperinflammatory phase of COVID-19. The studies provide a comprehensive assessment and potential approaches for optimizing emergency response systems and global public health threats. The problems associated with the purchase of pharmaceutical products and vaccines, their provision and the adequate control of rational drug therapy have been analyzed in detail, incl. for medicinal products that are not authorized for use in our country. The urgent need for a multimodal approach and

operational cooperation between different departments in the relevant regulatory bodies and health authorities is emphasized.

The problems caused by the current policies for the regulation and registration of food additives have been studied, which emphasize the need to optimize and respectively change the legislative framework in order to ensure control over the quality and quantitative composition and follow-up of their safety. A specialized study was conducted to track the best-selling food supplement categories, and 820 community pharmacies from all over the country were tracked, which is a respectable number of tracked units for the scale of Bulgaria. In this study, dietary supplements are ranked by category and market share respectively. This study shows that most consumers find dietary supplements completely safe, attributing this to their natural composition.

In this connection, the study of the presence of undeclared ingredients in food supplements, which hide an undoubted potential for unwanted effects and interactions with competitively applied drug therapy, is particularly important. An interesting study of 20 dietary supplements recommended for erectile dysfunction was targeted for the presence of undeclared phosphodiesterase type V inhibitors (sildenafil, tadalafil and vardenafil). In line with other studies of this interesting type of supplement conducted abroad, in the study by Assoc. Prof. Georgiev and his team, it was found that 14 of the studied products contained sildenafil. Similar studies have been carried out to monitor the presence of substances prohibited by WADA, including anabolic steroids, in supplements recommended to enhance performance and recovery in athletes. The undeclared synthetic steroids methandienone, methyltestosterone, oxandrolone, stanozolol, methenolone, boldenone and androstenolone, etc., were found in 12 of the 23 food supplements examined, and the corresponding labels stated that the products do not cause side effects, and there is no age restriction. These products carry the risk not only of the unwanted effects of anabolic steroids, especially in adolescents and women, but also of ruining potentially successful careers in sports, in relation to control by the relevant anti-doping institutions.

Research has been conducted on the need to educate adolescents about the risks associated with drug abuse, drug addiction, and new pandemics of substance abuse, often mistakenly seen as harmless, including nitrous oxide, which is enjoying growing popularity in our country.

Other areas of research interests of Assoc. Prof. Georgiev include pharmaceutical care, therapy monitoring and therapeutic management.

4. Scientific projects.

It is clear from the submitted documents that Assoc. Mag. Pharm. Stanislav Georgiev, PhD, participated in one national project and two projects that received institutional financial support from the MU-Plovdiv.

5. Teaching activities and workload.

Assoc. Prof. Georgiev is actively involved in teaching pharmacy students in the disciplines of the department and on the profile of the competition. As can be seen from the submitted references, the candidate has a significant schedule of academic activities. Assoc. Prof. Stanislav Georgiev, has been the scientific supervisor of 5 successfully defended doctoral students, as well as of 10 board certification fellows in the specialty "Organization and economics of distribution and pharmacy practice".

6. Conclusion.

The in-depth analysis of the materials provided by Associate Professor Stanislav Georgiev gives me reason to believe that the candidate meets the explicit requirements for employment of AD "Professor" laid down in the national and institutional regulations. The candidate's scientific contributions and developments cover a significant part of the spectrum of the competition's specialty and demonstrate in-depth research and teaching activities and erudition. The quantitative requirements have been met, and in some of the domains for the assessment of AD candidates they have been even significantly exceeded. Prof. Georgiev has emerged as one of the promising young researchers and lecturers with multifaceted interests in the entire continuum of pharmaceutical regulation. All of this gives me reason to confidently give a positive assessment to the documents provided by the candidate and **to recommend to the honourable members of the scientific jury to support the appointment of AD "Professor" in the scientific specialty "Pharmacoeconomics and pharmaceutical regulation" by Assoc. Prof. Stanislav Georgiev, PhD.**

9th September, 2024 г.

Reviewer:

/Prof. Georgi Momekov, DSc /

Заличено на основание
Чл.5 §1, б."В" Регламент (ЕС)2016/679